Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

Basit Öğe Kaydı
dc.authoridbilgin, burak/0000-0003-1717-8246
dc.authoridYaşar, Hatime Arzu/0000-0002-0545-1383
dc.authoridErturk, Ismail/0000-0001-6835-0988
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridKilickap, Saadettin/0000-0003-1637-7390
dc.authoridUcar, Gokhan/0000-0002-7649-1075
dc.authoridÜrün, Yüksel/0000-0002-9152-9887
dc.authorwosidbir yucel, kadriye/HGE-4410-2022
dc.authorwosidArslan, Cagatay/I-1932-2016
dc.authorwosidKarakaya, Serdar/ABF-6887-2021
dc.authorwosidbilgin, burak/A-9416-2018
dc.authorwosidYaşar, Hatime Arzu/HGC-5631-2022
dc.authorwosidErturk, Ismail/B-4317-2019
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.contributor.authorHizal, Mutlu
dc.contributor.authorSendur, Mehmet A. N.
dc.contributor.authorYasar, Hatime Arzu
dc.contributor.authorBir Yucel, Kadriye
dc.contributor.authorArslan, Cagatay
dc.contributor.authorUcar, Gokhan
dc.contributor.authorKarakaya, Serdar
dc.date.accessioned2024-06-12T11:03:54Z
dc.date.available2024-06-12T11:03:54Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground To describe the prognostic value of neutrophil-lymphocyte ratio and its effect on survival in in patients with advanced renal cell carcinoma. Methods We retrospectively analyzed 331 patients. The cut-off value of neutrophil-lymphocyte ratio was specified as 3 which is mostly close-and also clinically easily applicable-to the median neutrophil-lymphocyte ratio level of our study group. High group is identified as neutrophil-lymphocyte ratio >3 (n = 160) and low group is identified as neutrophil-lymphocyte ratio <= 3 (n = 163). Results A total of 331 (with 211 male and 120 female) patients were enrolled to study. The median age of the patients was 58. The International Metastatic RCC Database Consortium risk score is calculated for the 72.8% (n = 241) of the study group and among these patients, favorable, intermediate, and poor risk rates were 22, 45.2, and 32.8%. The total usage of tyrosine kinase inhibitors reached 78% of the patients. The median overall survival was 32 months versus 11 months in the neutrophil-lymphocyte ratio low and high groups, respectively (HR: 0.49 (95% CI 0.37-0.65), p < 0.001). Conclusion In conclusion, the pre-treatment value of elevated neutrophil-lymphocyte ratio might be a predictor of poor overall survival in advanced renal cell carcinoma patients.en_US
dc.identifier.doi10.1177/1078155219900908
dc.identifier.endpage1589en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue7en_US
dc.identifier.pmid32054412en_US
dc.identifier.scopus2-s2.0-85079721796en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1583en_US
dc.identifier.urihttps://doi.org/10.1177/1078155219900908
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21833
dc.identifier.volume26en_US
dc.identifier.wosWOS:000513403600001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInterferonen_US
dc.subjectNeutrophil-Lymphocyte Ratioen_US
dc.subjectPrognosisen_US
dc.subjectRenal Cell Canceren_US
dc.subjectTyrosine Kinase Inhibitorsen_US
dc.subjectPretreatment Neutrophilen_US
dc.subjectInflammationen_US
dc.subjectCanceren_US
dc.subjectImpacten_US
dc.subjectProgressionen_US
dc.subjectValidationen_US
dc.titleNeutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu